Placeholder Banner

BIO Statement on EPA/FDA/USDA Release of Plans for Reforming Regulation of Animal, Microbial and Plant Biotechnology

May 8, 2024
Media Contact
Lynne Headshot

“BIO is pleased to see today’s report released by EPA, FDA and USDA outlining the joint plan for regulatory reform under the Coordinated Framework for Regulation of Biotechnology to support and sustain biotech innovation and continue growing the U.S. bioeconomy.

“We have been waiting for the Administration to put tangible policy behind the commitments outlined in President Biden’s Executive Order 14081, including reducing regulatory ambiguities, increasing interagency coordination and improving communication to reduce inefficiencies.

“Developers of plant, animal and microbial biotechnology are innovating rapidly to meet the challenges we face, from addressing climate change to ensuring we can feed a growing world. We need a regulatory process that works at the speed of today’s innovation. The agencies lay out in this report a plan to update existing guidance, develop new guidance and streamline processes.

“BIO is also pleased to see the joint news release from the agencies, signaling clear efforts to align and work together.

“We look forward to delving into today’s announcement with BIO members and analyzing its impact on the industry we represent.”

Discover More
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on the reintroduction of the bipartisan Pioneering Antimicrobial Subscriptions to End Upsurging Resistance …
WASHINGTON, D.C. –  John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement.“The passage of the Mikaela Naylon Give Kids a Chance Act is a bipartisan victory for children and…
Washington, D.C. (February 2, 2026) -- The Biotechnology Innovation Organization (BIO) today named Joe Franklin, JD, PhD, as its new chief legal and policy officer. Franklin brings deep expertise in the biomedical sector across law, policy, AI, and…